
Biomimetic Innovations (BMI) executed an exclusive license and distribution agreement with Sanara MedTech. In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Sanara acquired exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and a hardware-agnostic adjunctive internal fixation technology featuring novel delivery to promote targeted application of OsStic for use in fracture management. The License and Distribution Agreement is for an initial five-year period, with the option to automatically renew for successive two-year periods at Sanara’s discretion.
OsStic is a disruptive new bio-adhesive bone void filler technology which was granted a Breakthrough Device Designation by FDA in 2023.
The proposed indication statement for OsStic is [a] “structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of periarticular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.”
Source: Biomimetic Innovations Ltd and PBC Biomed
Biomimetic Innovations (BMI) executed an exclusive license and distribution agreement with Sanara MedTech. In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Sanara acquired exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and a...
Biomimetic Innovations (BMI) executed an exclusive license and distribution agreement with Sanara MedTech. In tandem, Sanara agreed to make a minority investment in cash for equity in BMI.
Sanara acquired exclusive U.S. marketing, sales, and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler and a hardware-agnostic adjunctive internal fixation technology featuring novel delivery to promote targeted application of OsStic for use in fracture management. The License and Distribution Agreement is for an initial five-year period, with the option to automatically renew for successive two-year periods at Sanara’s discretion.
OsStic is a disruptive new bio-adhesive bone void filler technology which was granted a Breakthrough Device Designation by FDA in 2023.
The proposed indication statement for OsStic is [a] “structural, mechanically enhanced bioadhesive for reduction, provisional fixation, or void filling of periarticular fractures or defects to enhance structural stability where standard fixation alone cannot provide sufficient support for functional mobilization.”
Source: Biomimetic Innovations Ltd and PBC Biomed
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.